Print

Adamis Pharmaceuticals Reports APC-300 Kills Human Prostate Cancer Cells  
7/20/2011 8:31:46 AM

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced today that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells.
//-->